WS
RNAC icon

Wedbush Securities’s Cartesian Therapeutics RNAC Stock Holding History

Wedbush Securities’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Sell
10,500
-1,000
-9% -$7.41K ﹤0.01% 1271
2026
Q1 		$71K Buy
+11,500
New +$81.9K ﹤0.01% 1209

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wedbush Securities's RNAC Position: Q2 2026 in Review

Wedbush Securities reduced its Cartesian Therapeutics (RNAC) stake by 8.7% in Q2 2026, selling an estimated $7.41K and leaving 10,500 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #1271.

Wedbush Securities first reported a position in RNAC in Q1 2026 and has held it in 2 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Wedbush Securities held 10,500 shares of Cartesian Therapeutics worth $109K as of Q2 2026.
  • Wedbush Securities sold 1,000 Cartesian Therapeutics shares in Q2 2026, an estimated $7.41K.
  • Cartesian Therapeutics made up ﹤0.01% of Wedbush Securities's portfolio in Q2 2026, its #1271 holding.
  • Wedbush Securities first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Wedbush Securities's 13F filing for Q2 2026, filed 28 Jul 2026.